- Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2018 Academic Article GET IT
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents.
Journal of Clinical Oncology.
Times cited: 23
The european hematology association roadmap for european hematology research: A consensus document.
Times cited: 26